Pharmaceuticals
10 biosimilar launch experts
These ten professionals have worked on biosimilar launches in their own roles at pharmaceutical companies. A reader can learn from them how teams plan, prepare and carry out biosimilar launches in different markets.
Professionals to explore
01—10Andrea Brambilla
LinkedInExperience: Biosimilar Europe Operations and Launch Excellence Manager · Sandoz
Biosimilar Europe Operations and Launch Excellence Manager at Sandoz since July 2026, a title that names biosimilar launch excellence directly. The profile also lists a Sales & HEOR Specialist role at Sandoz Italia since January 2025 and Sales Operation Analyst Biosimilars at Sandoz (2023–2024).
Anjana Kavikkal
LinkedInExperience: Head Commercial Operations, Alliance Management Europe & Marketing · Dr. Reddy's Laboratories
Head Commercial Operations, Alliance Management Europe & Marketing at Dr. Reddy's Laboratories since March 2024. The profile says this work leads alliance management, marketing and commercial operations for Europe, driving biosimilar launches. Other Dr. Reddy's roles listed include Lead, Commercial Operations & Packaging (2020–2024) and Associate Director, Alliance Management (2012–2016).
Chris Bertolino, MBA
LinkedInExperience: U.S. Brand Lead, Denosumab Biosimilar Launch · Sandoz
U.S. Brand Lead, Denosumab Biosimilar Launch at Sandoz since June 2023, where the profile says the role leads the development and implementation of the US marketing strategy and commercial success of the Sandoz denosumab biosimilar launch in the osteoporosis and oncology segments. At Amgen the profile lists Sr. Marketing Manager, U.S. Oncology Marketing (2018–2019) and Director, Commercial Center of Learning Excellence (2019–2023).
Christine Cannon
LinkedInExperience: Director, Biosimilar Pipeline · Sandoz
Former Director, Biosimilar Pipeline at Sandoz (2022–2026), where the profile says the role acted as US commercial lead on global project teams for the launch preparation of several mid to long term assets and developed business cases for new global pipeline opportunities. The profile also lists Senior Director, Global Marketing Biosimilars at Teva Pharmaceuticals (2020–2022) and AVP - Head Global Marketing- Biosimilars at Sanofi (2017–2020).
Curtis Bamber
LinkedInExperience: Lead - Biosimilars Marketing & Sales Commercial Team · Pfizer
Former Lead - Biosimilars Marketing & Sales Commercial Team at Pfizer (2015–2018) and former Head of Marketing & Biosimilars - Canada at Hospira (2012–2015). The profile describes leading multiple launches across therapeutic areas and product classes, including hepatitis C, biologics and the first infliximab biosimilar, and also lists Lead - International Retail Strategy at Pfizer (2023–2024).
Laura Rodgers
LinkedInExperience: Director, Global Launch Lead, IgG4 UPLIZNA · Amgen
The profile lists a four-month role as Director, Biosimilars, Byooviz US Launch Lead, from January 2022 to May 2022, based in Cambridge, Massachusetts. She has been Director, Global Launch Lead, IgG4 UPLIZNA at Amgen since July 2023, and was Director, HCP Marketing, KRYSTEXXA at Horizon (2022–2023).
Mark Nieuwenhuis
LinkedInExperience: Associate Director Key Accounts - South East · Sandoz
Associate Director Key Accounts - South East at Sandoz (2014–2016) and Director Regional Accounts - Oncology at Sandoz (2016–2022), and Director National Accounts at Sandoz US since 2026. A highlight on the profile describes leading 9 key account managers in FL, GA, AL, TN, SC, NC and KY and says: 'We are launching the first BioSimilar in the USA - Zarxio.'
Pawan Tiwary
LinkedInExperience: VP & Head of Global Program Management and Portfolio Strategy - Biosimilars & Novels · Intas Pharmaceuticals
VP & Head of Global Program Management and Portfolio Strategy - Biosimilars & Novels at Intas Pharmaceuticals since November 2021. The profile says this leadership focuses on biosimilars and that the team has navigated biosimilar product approvals and strategic launches. The profile also lists Senior Director, Global Program Management Biosimilars Development at Biocon Biologics (2015–2021).
Ruan de Wet
LinkedInExperience: US Biosimilars Commercial Lead · Teva Pharmaceuticals
US Biosimilars Commercial Lead at Teva Pharmaceuticals since June 2026, a role the profile describes as responsible for Teva US Biosimilars asset launches and in-line portfolio management, including P&L management. The profile also lists Head, US Biosimilars Strategy & Planning (Marketing) at Teva Pharmaceuticals (2025–2026) and Executive Director, Global Marketing at Novartis (2023–2024).
Sang-e Nahm
LinkedInExperience: Senior Manager at Commercial Strategy Team · Samsung Bioepis
Senior Manager at Commercial Strategy Team at Samsung Bioepis since 2019. The profile lists a 2019 new market launch strategy for immunology biosimilars to Israel and Saudi Arabia, work as Benepali brand manager for the EU market from 2021, and Stelara biosimilar brand manager and launch readiness for the US, EU and Canadian markets from 2022.
Choose the right perspective
Match the person's role to your question: brand and commercial leads suit questions about launch strategy and positioning, while operations, account and program roles suit questions about launch readiness and execution. Also consider which market the person worked in, since launch conditions can differ between countries and regions.
Questions to take into the conversation
- 01How did you decide on launch timing and pricing for a biosimilar entering a market against the reference product?
- 02What did you do to win formulary or tender access and prescriber adoption in the first year after launch?
- 03Which launch readiness steps, such as supply, contracting and field preparation, caused the most problems, and how did you handle them?
Reaching biosimilar launch experts
How can I contact one of these biosimilar launch experts?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 7 companies, including Sandoz, Dr. Reddy's Laboratories and Pfizer, based on profile data retrieved on October 3, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach biosimilar launch experts?
You choose the offer, starting at $5 per person. It includes Instant Expert's 20% fee, so an offer that pays the person $100 costs you $125. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal